Novel Subcutaneous Biologics Show Promise in AD

Patients with moderate to severe atopic dermatitis could soon have more therapeutic options, with monoclonal antibodies targeting novel immune pathways that reduce disease severity, suggest two trials.

Related Keywords

Germany ,Oregon ,United States ,Amsterdam ,Noord Holland ,Netherlands ,Portland ,Eric Simpson ,Stephan Weidinger ,Tiagor Matos ,Department Of Dermatology ,European Academy Of Dermatology ,Kymab Ltd ,University Hospital Schleswig Holstein ,Amsterdam University Medical Centers ,Oregon Health Science University ,European Academy ,Eczema Area ,Severity Index ,Oregon Health ,Science University ,Medscape Medical News ,Validated Investigator Global Assessment ,Atopic Dermatitis ,Body Surface Area ,Peak Pruritus Numerical Rating Scale ,Dermatitis ,Biologic Therapy ,Monoclonal Antibody ,Etuximab ,Ituximab ,Conjunctivitis ,Corneal Disease ,Allergy ,Cytokines ,Receptors ,Antigens ,Eczema ,Europe ,European ,Hospitals ,Interleukins ,Preventive Screening ,Screening ,Pruritus ,Pruritis ,Pitch ,Severity Indices ,